After four intensive days in Boston, it’s clear that our industry is navigating a period of both remarkable innovation and significant headwinds. Here’s what caught my attention as someone who’s spent decades in oncology clinical development.
The buzz around AI-driven drug discovery was palpable, but the conversations were refreshingly pragmatic. Sessions on “AI-driven drug development” generated significant buzz, with leaders sharing how large language models, structural prediction algorithms, and automated analytics are accelerating target validation and drug candidate screening. What struck me wasn’t the hype, but the honest discussions about what’s actually working versus what’s still theoretical. For clinical teams, the key takeaway is that AI tools are becoming genuinely useful for patient stratification and biomarker identification—but they’re supplements to, not replacements for, solid clinical strategy.
The data on oncology pipeline evolution was sobering yet encouraging. Small molecule drugs now account for less than half (45%) of oncology pipelines, while novel therapies like antibody-drug conjugates (ADCs), cell therapies, cancer vaccines, and radiopharmaceuticals are gaining traction, comprising 15% of the pipeline. This isn’t just academic—it’s reshaping how we think about trial design, regulatory pathways, and manufacturing partnerships.
For mid-size companies, this trend creates both opportunity and pressure. The complexity of these modalities means we need to be even smarter about vendor selection and regulatory strategy from day one.
Let’s address the elephant in the room. Venture capital—the lifeblood of early-stage biotechs—is retreating rapidly, with early-stage deal values hitting a four-year low. Deep funding cuts to the National Institutes of Health could dim innovation, while FDA staffing reductions have already lengthened some review times and increased regulatory costs.
The silver lining? Companies with strong fundamentals and clear clinical strategies are still finding support. The session on emerging biotech investment trends highlighted that quality assets with well-designed protocols are attracting strategic partnerships, even in this challenging environment.
With over 62,000 partnering meetings scheduled over the four days, the emphasis on collaboration between companies and between government and industry was unmistakable. What impressed me was the increasing sophistication of these partnerships. Companies are moving beyond simple licensing deals to more nuanced collaborations around regulatory strategy, manufacturing, and global market access.
The regulatory sessions provided needed clarity on several fronts. FDA Commissioner Martin Makary’s remarks offered reassurance about the agency’s commitment to innovation, despite resource constraints. The discussions around antimicrobial resistance highlighted opportunities for companies working in infectious diseases, particularly around new incentive structures and expedited pathways.
Here are three practical takeaways for clinical development teams:
The industry remains fundamentally strong, but success requires more strategic thinking than ever. The companies that will thrive are those that combine scientific excellence with smart business development and regulatory acumen.
The author, Dr. Dan Weng, attended BIO 2025 as CEO of Medelis, a specialty CRO with an oncology focus. Views expressed are his own. Contact Medelis to learn more.